In PsA, the phase 3b TOGETHER-PsA trial (NCT06588296) assesses the combined use of ixekizumab and tirzepatide in patients with active disease and concomitant overweight or obesity, while the phase 4 TOGETHER AMPLIFY-PsA study (NCT06864026) examines the effectiveness of adding tirzepatide to ixekizumab in clinical practice over 12 months
Additionally, tirzepatides anorexigenic effect might exceed that of GLP-1RAs by integrating the activation signals of both GIP and GLP-1 receptor pathways in the brain 7,9
"In general, patients should avoid added sugar and processed food or what we may know as 'junk food' as much as possible," Dr
Effective weight-loss treatments will unquestionably increase short-term pharmacy plan spending, with the potential to reduce longer-term medical plan costs by avoiding some of the harmful complications of diseases that are driven, in part, by obesity
One case report has been received of adverse reactions with phentermine and fluoxetine